Not known from ADAM(TS-13) - Novel insights into the pathophysiology of thrombotic microangiopathies

Nephrology Dialysis Transplantation

Volumn 19, Issue 7, 2004, Pages 1687-1693

  Wolf, Gunter ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

ADAMTS 13; Haemolytic uraemic syndrome; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

DISINTEGRIN; MEMBRANE COFACTOR PROTEIN; METALLOPROTEINASE; VON WILLEBRAND FACTOR;

EDITORIAL; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SYMPTOMATOLOGY; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADAM PROTEINS; DIAGNOSIS, DIFFERENTIAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS; METALLOENDOPEPTIDASES; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 3242704913     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh268     Document Type: Editorial

References (40)

1. Ruggenenti P, Remuzzi G. Pathophysiology and management of thrombotic microangiopathies. J Nephrol 1998; 11: 300-310
2. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32: 292-308
3. Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21-24
4. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600
5. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60: 831-846
6. Moake J, Rudy C, Troll J et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-1435
7. Asada Y, Sumiyoshi A, Hayashi T et al. Immunochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985; 38: 469-479
8. Furlan M, Robles R, Galbusera M et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584
9. Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594
10. Levy GG, Nichols WC, Lian EC et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494
11. Tsai HM. Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 2001; 23: 388-396
12. Chung DW, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochem 2002; 41: 11 065-11 070
13. Zheng X, Pallera AM, Goodnough LT, Sadler E, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138: 105-108
14. Rock GA, Shumak KH, Buskard NA et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991; 325: 393-397
15. Assink K, Schiphorts R, Allford S et al. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 2003; 63: 1995-1999
16. Garg AX, Suri RS, Barrowman N et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome. J Am Med Assoc 2003; 290: 1360-1370
17. Siegler RL. Postdiarrheal shiga toxin-mediated hemolytic uremic syndrome. J Am Med Assoc 2003; 10: 1379-1381
18. Smith WE, Kane AV, Campbell ST et al. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect Immun 2003; 71: 1497-1504
19. Hurley BP, Thorpe CM, Acheson DWK. Shiga toxin translocation across intestinal epithelial cells is enhanced by neutrophil transmigration. Infect Immun 2001; 69: 6148-6155
20. te Loo DM, Monnens LA, van der Velden TJ et al. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000; 95: 3396-3402
21. Arab S, Lingwood CA. Intracellular targeting of the endoplasmic reticulum/nuclear envelope by retrograde transport may determine cell hypersensitivity to verotoxin via globotriaosyl ceramide fatty acid isoform traffic. J Cell Physiol 1998; 177: 646-660
22. Chandler WE, Jelacic S, Boster DR et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002; 346: 23-32
23. Capriolo J, Bettinaglio P, Zipfel PF et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12: 297-307
24. Pangburn MK. Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome. J Immunol 2002; 169: 4702-4706
25. Manuelian T, Hellwage J, Meri S et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181-1190
26. Noris M, Briosche S, Caprioli J et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542-1547
27. Bianchi V, Robles R, Alberio L, Furlan M. Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 2002; 100: 710-713.
28. Tsai HM, Chandler WL, Sarode R et al. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli 0157:H7-associated hemolytic uremic syndrome. Ped Res 2001; 49: 653-659
29. Hunt BJ, Lämmle B, Nevard CHF, Haycock GB, Furlan M. Von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85: 975-978
30. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001; 98: 1765-1772
31. Remuzzi G, Galbusera M, Noris M et al. Von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood 2002; 100: 778-785
32. Moore JC, Hayward CPM, Warkentin TE, Kelton JG. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood 2001; 98: 1842-1846
33. Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88: 1029-1034
34. Vesely SK, George JN, Lämmle B et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003: 102: 60-68
35. Tsai HM. Deficiency of ADAMTS-13 and thrombotic thrombocytopenic purpura [letter]. Blood 2002; 100: 3839
36. Lämmle B, Bianchi V, Alberio L, Furlan M. ADAMTS13 and thrombotic thrombocytopenic purpura [letter]. Blood 2002; 100: 3840-3841
37. Remuzzi G, Glabusera M, Mannucci PM. ADAMTS13 in thrombotic microangiopathies [letter]. Blood 2002; 100: 3842
38. Moake JL. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Arch Pathol Lab Med 2002; 126: 1430-1433
39. Allford SL, Hunt BJ, Rose P, Machin SJ. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003; 120: 556-573
40. Shah NT, Rand JH. Controversies in differentiating thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mt Sinai J Med 2003; 70: 344-351.